InvestorWire NewsRoom


Brain Scientific Inc. (BRSF) Offers Stock to Wider Pool of Investors Through Dalmore Group
November 17, 2020

Brain Scientific Inc. (BRSF) Offers Stock to Wider Pool of Investors Through Dalmore Group

  • BRSF announce partnership with Dalmore Group
  • New product launch presents solution for growing need for rapid EEG testing due to COVID-19 pandemic
  • Brain Scientific shose to extend proposed Reg A+ offering to attract additional investors

Brain Scientific (BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, has announced a partnership with the Dalmore Group in a recent press release (

“We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.”

The Dalmore Group is a member of FINRA and SIPC with an active presence in the Regulation A+ equity funding space. As one of the most active broker-dealers in the world, the company has served as broker-dealer on more than 50 RegA+ offerings in the past 12 months alone. In 2019 the Dalmore Group raised over $1 billion of capital. The majority of Dalmore Group’s clients come by referral from securities attorneys and industry participants.

BRSF is looking to the Dalmore Group for its expert strategic advice and innovative solutions. The Dalmore Group prides itself on understanding a client’s critical business processes and financial goals in order to provide the most comprehensive services possible.

Brain Scientific recently launched the next-gen, 19-channel NeuroCap(TM) device. This is a hospitable-grade disposable EEG headset that presents a solution for the growing need for rapid EEG testing due to the COVID-19 pandemic. Through the use of a special adapter, the NeuroCap is compatible with any other amplifiers of EEG signals.

Two of the biggest challenges of administering EEGs is the need to measure a patient’s head and the time needed to place the electrodes accurately. This required a specialized neurological technician. The pre-gelled fixed electrode locations, in accordance with the International 10-20 System, allow the NeuroCap to be administered by any healthcare worker making it more accessible to a larger group of patients.

The ease of use opens the device up for application in hospitals, clinics and rural areas where medical resources may be limited. Also, the global pandemic is still raging, and new studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing (

“With our recent product development and new product launches,” said Goldstein, “we feel the need to extend the proposed Regulation A+ Offering to attract additional investors, which we believe we can better accomplish by working with Dalmore.” 

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).